Clinical Trials

Pharmaceutical Outsourcing Clinical Trials Patient Vitals Abstract Image

Clinical trials are conducted to evaluate and test new pharmaceuticals before they are approved and brought to market. Clinical trials were traditionally conducted in three phases, with a fourth phase added to monitor post-marketing findings. The trials at each phase have a different purpose and help researchers evaluate the potential treatment in a number of ways to ensure its safety and efficacy.

Phase I trials

Researchers test an experimental drug or treatment in a small group of people for the first time. The researchers evaluate the treatment’s safety, determine a safe dosage range, and identify side effects.

Phase II trials

The experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase III trials

The experimental study drug or treatment is given to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.

Phase IV trials

Post-marketing studies, which are conducted after a treatment is approved for use by the FDA, provide additional information including the treatment or drug’s risks, benefits, and best use.

Filter

Hide Filter
  • Biofidelity and CellCarta Announce Partnership

    Thursday, January 16, 2025
    Biofidelity, and CellCarta announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials. read more
  • Enhanc3D Genomics Launches 3D Multi-Omics Solutions

    Tuesday, January 14, 2025
    Based on the Company’s proprietary 3D genomics platform, integrated with extensive multi-omics analysis, the new 3D Multi-omic offerings provide partners with a powerful end-to-end solution to support and enhance decision-making through every stage ... read more
  • dbDNA™ Manufacturing Facility Receives GMP License from MHRA

    Tuesday, January 14, 2025
    Touchlight has received a Manufacturer’s Authorization for Investigational Medicinal Products (MIA, IMP) license from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the GMP (Good Manufacturing Practices) production of ... read more
  • Alcami Names New CEO

    Tuesday, January 14, 2025
    Alcami Corporation announced the resignation of Bill Humphries. Alcami’s Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from ... read more
  • Avéma Pharma Solutions Moved Under PLD Banner

    Tuesday, January 14, 2025
    With this move, PLD is consolidating its divisions with a unified identity that reflects the company’s commitment to developing and manufacturing high quality, liquid and solid dose OTC and Rx products to its customers. read more
  • ActiGraph Acquires Biofourmis Life Science Business

    Tuesday, January 07, 2025
    ActiGraph has announced the acquisition of Biofourmis Connect, a division of Biofourmis that delivers an AI-driven, digital trial platform tailored for the life science industry. The combined solution will create a market-leading, unified software ... read more
  • Platinum Press Expands Headquarters by 70,000 SF in $15M Investment

    Tuesday, January 07, 2025
    Platinum Press, Inc., a provider of printed packaging solutions for the pharmaceutical, natural health and consumer products industries specializing in labels, folding cartons, leaflets, foil lidding and flexible packaging, has completed a $15 ... read more
  • Gaelic Laboratories Expands Into the Middle East

    Tuesday, January 07, 2025
    Gaelic Laboratories has established a Commercial Arm in the UAE that enables the company to import, register, market and distribute medicines in the Middle East. With its newly opened Gaelic Drug Store LLC in Dubai, the company now has an ... read more
  • Veeda Group Rebrands as Veeda Lifesciences

    Thursday, January 02, 2025
    Veeda Group has unveiled a new logo and brand identity - Veeda Lifesciences. The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise for different modalities of ... read more
  • I Peace Announces Manufacture of 100 lines of GMP iPS Cells Cumulatively

    Thursday, January 02, 2025
    GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the number of GMP-grade iPS cells manufactured has reached 100 lines. read more
  • Scinai Immunotherapeutics Establishes US-Based Scinai Bioservices Inc.

    Thursday, December 19, 2024
    Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced the establishment of a U.S.-... read more
  • Novo Holdings Completes Acquisition of Catalent

    Thursday, December 19, 2024
    Catalent, Inc. and Novo Holdings A/S announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. read more
  • Aramis Biotechnologies and Biodextris Announce Partnership

    Thursday, December 19, 2024
    Aramis Biotechnologies Inc. and Biodextris Inc. announced a strategic partnership that will leverage the expertise of both companies to ensure efficient downstream manufacturing of clinical materials for Aramis' leading product candidate, a seasonal ... read more
  • BioCentriq Expands Operations and Secures Cell Therapy Manufacturing Facility in Princeton, NJ

    Tuesday, December 17, 2024
    BioCentriq has entered into a long-term lease agreement with National Business Parks for a state-of-the-art cell therapy manufacturing facility in Princeton, New Jersey. The facility will serve as the company's new headquarters and will include an ... read more
  • MediPharm Labs Sells Facility to Kensana Health

    Tuesday, December 17, 2024
    MediPharm Labs Corp. and Kensana Health Inc. have entered into a share purchase agreement for the purchase and sale of MediPharm's facility in Napanee, Ontario for $5.5 million in cash. read more